Ganciclovir ophthalmic - Laboratoires Thea
Alternative Names: Ganciclovir ophthalmic gel 0.15%; ST-605; Virgan; ZirganLatest Information Update: 02 Oct 2021
At a glance
- Originator Laboratoires Thea
- Developer Laboratoires Thea; Ms Science; Sirion Therapeutics
- Class Antineoplastics; Antivirals; Hypoxanthines; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ocular herpes simplex
- Phase II Cytomegalovirus infections; Dendritic keratitis
Most Recent Events
- 23 Feb 2021 Ganciclovir ophthalmic is still in phase II trials for Dendritic keratitis in Japan (Ophthalmic) (JapicCTI-183901)
- 08 Dec 2020 Northwestern University terminates phase II trial in Herpes zoster keratitis in USA due to difficulties meeting enrollment goal (NCT02382588)
- 01 Apr 2018 Phase-II clinical trials in Dendritic keratitis in Japan (Ophthalmic) (JapicCTI-183901)